BRIYAL S ET AL: "Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia", NEUROSCIENCE, NEW YORK, NY, US, vol. 281, 6 October 2014 (2014-10-06), pages 269 - 281, XP029090185, ISSN: 0306-4522, DOI: 10.1016/J.NEUROSCIENCE.2014.09.064 (B1)

DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2011 (2011-06-01), WU JING ET AL: "Long term health outcomes of liraglutide combined with metformin in type 2 diabetes patients: an analysis using CORE diabetes model", XP002760353, Database accession no. PREV201100516436 (B1)

JAMES P SMITH: "SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous use", INTERNET CITATION, 23 December 2014 (2014-12-23), XP002760221, Retrieved from the Internet <URL:http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf> [retrieved on 20160726] (B1)

KIP KEVIN E ET AL: "The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 51, no. 7, 10 February 2008 (2008-02-10), pages 701 - 707, XP029649101, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2007.10.034 (B1)

M. H. NOYAN-ASHRAF ET AL: "GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice", DIABETES, vol. 58, no. 4, 1 April 2009 (2009-04-01), US, pages 975 - 983, XP055291253, ISSN: 0012-1797, DOI: 10.2337/db08-1193 (B1)

MANFREDI RIZZO ET AL: "Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 100, no. 2, 1 February 2015 (2015-02-01), US, pages 603 - 606, XP055291826, ISSN: 0021-972X, DOI: 10.1210/jc.2014-2291 (B1)

ZAVATTARO MARCO ET AL: "One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study", ENDOCRINE, HUMANA PRESS, INC, US, vol. 50, no. 3, 9 January 2015 (2015-01-09), pages 620 - 626, XP035564833, ISSN: 1355-008X, [retrieved on 20150109], DOI: 10.1007/S12020-014-0519-0 (B1)

RAYMOND T ET AL: "Management of the patient with diabetes and coronary artery disease: A contemporary review", FUTURE CARDIOLOGY, FUTURE MEDICINE LTD., LONDON, GB, vol. 9, no. 3, 1 May 2013 (2013-05-01), pages 387 - 403, XP009191139, ISSN: 1479-6678 (B1)

SCHEEL-THOMSEN J ET AL: "Diabetes and stroke: liraglutide is associated with a decreased risk of stroke in type 2 diabetes mellitus. A nested case-control study", EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS, GB, vol. 21, no. Suppl.1, 1 May 2014 (2014-05-01), pages 154, XP009191130, ISSN: 1351-5101 (B1)

STEVEN P. MARSO ET AL: "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, vol. 375, no. 4, 28 July 2016 (2016-07-28), pages 311 - 322, XP055294203, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1603827 (B1)

US-A1- 2003 220 255 (B1)

VERGE D ET AL: "Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes", CURRENT DIABETES REVIEWS, BENTHAM SCIENCE PUBLISHERS, vol. 6, no. 4, 1 January 2010 (2010-01-01), pages 191 - 200, XP009191141, ISSN: 1573-3998 (B1)

WU JING ET AL: "Long term health outcomes of liraglutide combined with metformin in type 2 diabetes patients: an analysis using CORE diabetes model", ZHONGGUO XINYAO YU LINCHUANG ZAZHI, vol. 30, no. 6, June 2011 (2011-06-01), pages 422 - 427, ISSN: 1007-7669 (B1)

MUNDIL DHANWANTEE ET AL: "GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.", DIABETES & VASCULAR DISEASE RESEARCH APR 2012, vol. 9, no. 2, April 2012 (2012-04-01), pages 95 - 108, XP002760354, ISSN: 1752-8984 (B1)